<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00317876</url>
  </required_header>
  <id_info>
    <org_study_id>1288.00</org_study_id>
    <secondary_id>FHCRC-1288.00</secondary_id>
    <secondary_id>CDR0000481264</secondary_id>
    <nct_id>NCT00317876</nct_id>
  </id_info>
  <brief_title>Cyclophosphamide in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Fanconi's Anemia</brief_title>
  <official_title>Dose-Finding Study for Cyclophosphamide as Conditioning Regimens for Bone Marrow Transplantation From Related Donors in Patients With Fanconi Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as cyclophosphamide, before a donor bone&#xD;
      marrow transplant helps stop the growth of abnormal cells. It also stops the patient's immune&#xD;
      system from rejecting the donor's bone marrow. The donated bone marrow stem cells may replace&#xD;
      the patient's immune system and help destroy any remaining abnormal cells. Sometimes the&#xD;
      transplanted cells from a donor can also make an immune response against the body's normal&#xD;
      cells. Giving cyclosporine and methotrexate before or after transplant may stop this from&#xD;
      happening.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of cyclophosphamide in&#xD;
      treating patients who are undergoing a donor bone marrow transplant for Fanconi's anemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Decrease the conditioning-related toxicity of cyclophosphamide without decreasing the&#xD;
           engraftment rate to &lt; 90% in patients undergoing allogeneic bone marrow transplantation&#xD;
           for Fanconi's anemia.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-finding study of cyclophosphamide.&#xD;
&#xD;
        -  Nonmyeloablative conditioning regimen: Patients receive cyclophosphamide IV on days -5&#xD;
           to -2.&#xD;
&#xD;
      Cohorts of 5-10 patients receive decreasing doses of cyclophosphamide until the optimal dose&#xD;
      (OD) is determined. The OD is defined as the dose at which ≥ 4 of 5 patients achieve&#xD;
      engraftment and &lt; 1 of 10 patients experiences dose-limiting toxicity.&#xD;
&#xD;
        -  Allogeneic bone marrow transplantation (BMT): Patients undergo allogeneic BMT on day 0.&#xD;
&#xD;
        -  Graft-vs-host-disease (GVHD) prophylaxis: Patients receive cyclosporine orally or IV&#xD;
           twice daily beginning on day -1 and continuing until day 49, followed by a taper on days&#xD;
           50-180 in the absence of GVHD. Patients also receive methotrexate IV on days 1, 3, 6,&#xD;
           and 11.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1998</start_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Conditioning-related toxicity</measure>
    <time_frame>100 days post-transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Graft rejection</measure>
    <time_frame>100 days post-transplant</time_frame>
  </primary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Fanconi Anemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of Fanconi's anemia by chromosome fragility with a diepoxybutane (DEB) or&#xD;
             mitomycin C test&#xD;
&#xD;
               -  Hemoglobin ≤ 8.0 g/dL, absolute granulocyte count ≤ 1,000/mm^3, or platelet count&#xD;
                  ≤ 50,000/mm^3&#xD;
&#xD;
          -  No refractory anemia with excess blasts, refractory anemia with excess blasts in&#xD;
             transformation, or acute leukemia&#xD;
&#xD;
          -  HLA-identical related donor available&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Glomerular filtration rate ≥ 30% predicted for age&#xD;
&#xD;
          -  No liver disease (e.g., active hepatitis or moderate to severe portal&#xD;
             fibrosis/cirrhosis by biopsy)&#xD;
&#xD;
          -  No symptomatic cardiac insufficiency or symptomatic arrhythmia&#xD;
&#xD;
          -  No other diseases that would severely limit the probability of survival&#xD;
&#xD;
          -  No HIV seropositivity&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Peter Kiem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal do Parana</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80.060-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <study_first_submitted>April 24, 2006</study_first_submitted>
  <study_first_submitted_qc>April 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2006</study_first_posted>
  <last_update_submitted>April 18, 2012</last_update_submitted>
  <last_update_submitted_qc>April 18, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2012</last_update_posted>
  <responsible_party>
    <name_title>Hans-Peter Kiem, MD</name_title>
    <organization>Fred Hutchinson Cancer Research Center</organization>
  </responsible_party>
  <keyword>Fanconi anemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fanconi Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

